Lycopene (LYC) is known to protect cells from oxidative damage caused by free radicals in human tissues. In the present study, the authors designed a LYC-loaded sialic acid (SA)-conjugated poly(D,L-lactide-co-glycolide) (PLGA) nanoparticle (LYC-NP) to enhance the therapeutic efficacy of LYC in acute kidney injury. The characteristics of the LYC-NPs were defined according to particle size, morphology, and in vitro drug release. The LYC-NPs exhibited a controlled release of LYC over 48 h. Confocal laser scanning microscopy clearly highlighted the targeting potential of SA. Enhanced green fluorescence was observed for the LYC-NPs in H2O2-treated human umbilical vein endothelial cells, indicating enhanced internalisation of NPs. The LYC-NPs showed significantly greater cell viability than H2O2-treated cells. In addition, the LYC-NPs remarkably reduced proinflammatory cytokine levels, attributable mainly to the increased cellular internalisation of the SA-based carrier delivery system. Furthermore, protein levels of caspase-3 and -9 were significantly down-regulated after treatment with the LYC-NPs. Overall, they have demonstrated that SA-conjugated PLGA-NPs containing LYC could be used to treat kidney injury.

中文翻译：

---

唾液酸缀合的PLGA纳米颗粒增强番茄红素在化疗药物引起的肾损伤中的保护作用。

已知番茄红素 (LYC) 可保护细胞免受人体组织中自由基引起的氧化损伤。在本研究中，作者设计了一种负载 LYC 的唾液酸 (SA) 共轭聚 (D,L-lactide-co-glycolide) (PLGA) 纳米颗粒 (LYC-NP)，以增强 LYC 在急性肾病中的治疗效果。受伤。LYC-NPs 的特性是根据粒径、形态和体外药物释放来定义的。LYC-NPs 在 48 小时内表现出 LYC 的受控释放。共聚焦激光扫描显微镜清楚地突出了 SA 的靶向潜力。在 H2O2 处理的人脐静脉内皮细胞中观察到 LYC-NPs 的绿色荧光增强，表明 NPs 的内化增强。LYC-NPs 显示出比 H2O2 处理的细胞显着更高的细胞活力。此外，LYC-NPs 显着降低了促炎细胞因子水平，这主要归因于基于 SA 的载体递送系统的细胞内化增加。此外，在用 LYC-NPs 处理后，caspase-3 和 -9 的蛋白质水平显着下调。总体而言，他们已经证明含有 LYC 的 SA 共轭 PLGA-NP 可用于治疗肾损伤。